Home Newsfeeds Wells Fargo Maintains Overweight on Arthur J. Gallagher, Raises Price Target to $212

Wells Fargo Maintains Overweight on Arthur J. Gallagher, Raises Price Target to $212

Wells Fargo analyst Elyse Greenspan maintains Arthur J. Gallagher (NYSE:AJG) with a Overweight and raises the price target from $211 to $212.

byBenzinga Newsdesk

September 21, 2022

1 minute read

Wells Fargo analyst Elyse Greenspan maintains Arthur J. Gallagher (NYSE:AJG) with a Overweight and raises the price target from $211 to $212.

News
Tech

OpenAI’s New Model GPT-4o, Elon Musk’s High Regard For Ilya Sutskever And Microsoft’s China Move: This Week In Artificial Intelligence

By Benzinga Neuro

May 19, 6:30 AM

OpenAI unveils groundbreaking GPT-4o model, Microsoft urges AI team to relocate, and OpenAI's chief scientist resigns.

GOOG

Stantec Awarded $20M Contract For Gross Reservoir Expansion Project

By Benzinga Newsdesk

October 6, 6:47 AM

Stantec, a global leader in sustainable design and engineering, has been named Engineer of Record providing engineering support during construction for the second phase of the Gross Reservoir Expansion (GRE) Project in

STN

Cullinan Therapeutics To Present Clinical Data From Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, As Monotherapy And In Combination With A Checkpoint Inhibitor In Patients With Advanced Solid Tumors At ASCO 2024

By Benzinga Newsdesk

April 24, 10:10 AM

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid

CGEM